These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19426122)

  • 21. Experimental medication treatment approaches for depression.
    Ionescu DF; Papakostas GI
    Transl Psychiatry; 2017 Mar; 7(3):e1068. PubMed ID: 28323287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind, placebo-controlled study of paroxetine in depressed outpatients.
    Kiev A
    J Clin Psychiatry; 1992 Feb; 53 Suppl():27-9. PubMed ID: 1531818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
    Rouillon F
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S31-5. PubMed ID: 16436938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathobiological targets of depression.
    Chopra K; Kumar B; Kuhad A
    Expert Opin Ther Targets; 2011 Apr; 15(4):379-400. PubMed ID: 21254923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and Neuropeptides.
    Werner FM; Coveñas R
    Curr Pharm Des; 2019; 25(4):388-395. PubMed ID: 30969164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in the development of new antidepressants. Is there a light at the end of the tunnel?
    Pacher P; Kecskemeti V
    Curr Med Chem; 2004 Apr; 11(7):925-43. PubMed ID: 15078174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride.
    Kulkarni SK; Dhir A
    Eur J Pharmacol; 2007 Aug; 569(1-2):77-83. PubMed ID: 17585901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanism of action of antidepressants and therapeutic perspectives].
    Bourin M; David DJ; Jolliet P; Gardier A
    Therapie; 2002; 57(4):385-96. PubMed ID: 12422559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats.
    Rosenberg MB; Carroll FI; Negus SS
    J Pain; 2013 Mar; 14(3):246-59. PubMed ID: 23332494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desvenlafaxine for depression.
    Med Lett Drugs Ther; 2008 May; 50(1286):37-9. PubMed ID: 18487957
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacological treatment of adolescent major depression.
    Cohen D; Gerardin P; Mazet P; Purper-Ouakil D; Flament MF
    J Child Adolesc Psychopharmacol; 2004; 14(1):19-31. PubMed ID: 15142388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging targets for antidepressant therapies.
    Rakofsky JJ; Holtzheimer PE; Nemeroff CB
    Curr Opin Chem Biol; 2009 Jun; 13(3):291-302. PubMed ID: 19501541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
    Bourin M; Prica C
    Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors.
    Guiard BP; El Mansari M; Blier P
    Curr Drug Targets; 2009 Nov; 10(11):1069-84. PubMed ID: 19702555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
    de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
    Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classical neurotransmitters and neuropeptides involved in major depression in a multi-neurotransmitter system: a focus on antidepressant drugs.
    Werner FM; Coveñas R
    Curr Med Chem; 2013; 20(38):4853-8. PubMed ID: 24083608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obtained effect size as a function of sample size in approved antidepressants: a real-world illustration in support of better trial design.
    Gibertini M; Nations KR; Whitaker JA
    Int Clin Psychopharmacol; 2012 Mar; 27(2):100-6. PubMed ID: 22233698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The many different faces of major depression: it is time for personalized medicine.
    Korte SM; Prins J; Krajnc AM; Hendriksen H; Oosting RS; Westphal KG; Korte-Bouws GA; Olivier B
    Eur J Pharmacol; 2015 Apr; 753():88-104. PubMed ID: 25592320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating each and every depressed patient.
    Kennedy SH
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New perspectives on glutamate receptor antagonists as antidepressants.
    Chung C
    Arch Pharm Res; 2012 Mar; 35(4):573-7. PubMed ID: 22553049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.